Biểu đồ giá cổ phiếu GPCR
GPCR Dự đoán giá cổ phiếu
Structure Therapeutics Inc
$37.58
-3.78%
$-1.48
Khi đóng cửa: Jun 05, 16:00:00 GMT-4
$39.44
4.96%
$1.86
Phiên sau giờ: Jun 05, 20:00:00 GMT-4
Quay lại
Structure Therapeutics Inc (GPCR) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$39.06
Giá mở cửa
$39.26
Phạm vi ngày
$37.39 - $39.82
Phạm vi 52 tuần
$15.8 - $94.9
Khối lượng
515.1K
Khối lượng trung bình
1.0M
Tỷ suất cổ tức
--
EPS (TTM)
-0.83
Vốn hóa thị trường
$2.8B
GPCR là gì?
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
